Final Results for 12 months to 31 December 2020 and Notice of AGM
RNS & Investor News
01 September 2021
Notification and public disclosure of a transaction by a person discharging managerial responsibilities (PDMR).
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, diabetes and skincare, announces that it received notification on 31 August 2021 that René Kamminga (CEO, Optibiotix Ltd), acquired 8,188 ordinary shares in the Company on 31 August 2021 at a price of 55.4 pence per share.
Following the transaction, Mr Kamminga is interested in 43,188 ordinary shares in the Company, representing 0.05% of the Company's issued share capital.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc
Neil Davidson, Chairman
Contact via Walbrook below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD)
Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker)
Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
Details of the person discharging managerial responsibilities/person closely associated
Reason for notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
OptiBiotix Health Plc
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
8,188 ordinary shares of 2p each
Nature of the transaction
Purchase of 8,188 ordinary shares in the Company
Price(s) and volume(s)
Price(s) per share
Date of the transaction
31 August 2021
Place of the transaction
London Stock Exchange, AIM
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020